CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

BACKGROUND: Transthyretin amyloidosis, also called ATTR amyloidosis, is a life-threatening disease characterized by progressive accumulation of misfolded transthyretin (TTR) protein in tissues, predominantly the nerves and heart. NTLA-2001 is an in vivo gene-editing therapeutic agent that is designed to treat ATTR amyloidosis by reducing the concentration of TTR in serum. It is based on the clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease (CRISPR-Cas9) system and comprises a lipid nanoparticle encapsulating messenger RNA for Cas9 protein and a single guide RNA targeting TTR. METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: Preclinical studies showed durable knockout of TTR after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: In a small group of patients with hereditary ATTR amyloidosis with polyneuropathy, administration of NTLA-2001 was associated with only mild adverse events and led to decreases in serum TTR protein concentrations through targeted knockout of TTR. (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051. opens in new tab.

Application of Cardio-Forecasting for Evaluation of Human—Operator Performance

The paper presents the results of the development of the cardio-forecasting technology, which introduces a new method to monitor the state of human-operator, which is characteristic for the given production conditions and for individual operators, to predict the moment of exhaustion of his/her working capacity. The work aims to demonstrate the unique, distinctive features of the cardio-forecasting technology for predicting an individual limit of his/her working capacity for each person. A unique methodology for predicting individually for each person the moment when he/she reaches the limit of his/her working capacity is based on a spectral analysis of a human phonocardiogram in order to isolate the frequency component located at the heart contraction frequency. The trend of the amplitude of this component is approximated by its model; consequently, the coefficients of the trend model are determined. They include the operator’s operating time until his/her working capacity is exhausted. A methodology for predicting the moment when he/she reaches the limit of his/her working capacity for each person individually and assessment based on this degree of criticality of their condition will be realized as a software application for smartphones using the Android operating system

Application of cardio-forecasting for evaluation of human-operator performance

The paper presents the results of the development of the cardio-forecasting technology, which introduces a new method to monitor the state of human-operator, which is characteristic for the given production conditions and for individual operators, to predict the moment of exhaustion of his/her working capacity. The work aims to demonstrate the unique, distinctive features of the cardio-forecasting technology for predicting an individual limit of his/her working capacity for each person. A unique methodology for predicting individually for each person the moment when he/she reaches the limit of his/her working capacity is based on a spectral analysis of a human phonocardiogram in order to isolate the frequency component located at the heart contraction frequency. The trend of the amplitude of this component is approximated by its model; consequently, the coefficients of the trend model are determined. They include the operator’s operating time until his/her working capacity is exhausted. A methodology for predicting the moment when he/she reaches the limit of his/her working capacity for each person individually and assessment based on this degree of criticality of their condition will be realized as a software application for smartphones using the Android operating system.project KEG

Respiratory Syncytial Virus Human Experimental Infection Model: Provenance, Production, and Sequence of Low-Passaged Memphis-37 Challenge Virus

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in children and is responsible for as many as 199,000 childhood deaths annually worldwide. To support the development of viral therapeutics and vaccines for RSV, a human adult experimental infection model has been established. In this report, we describe the provenance and sequence of RSV Memphis-37, the low-passage clinical isolate used for the model's reproducible, safe, experimental infections of healthy, adult volunteers. The predicted amino acid sequences for major proteins of Memphis-37 are compared to nine other RSV A and B amino acid sequences to examine sites of vaccine, therapeutic, and pathophysiologic interest. Human T- cell epitope sequences previously defined by in vitro studies were observed to be closely matched between Memphis-37 and the laboratory strain RSV A2. Memphis-37 sequences provide baseline data with which to assess: (i) virus heterogeneity that may be evident following virus infection/transmission, (ii) the efficacy of candidate RSV vaccines and therapeutics in the experimental infection model, and (iii) the potential emergence of escape mutants as a consequence of experimental drug treatments. Memphis-37 is a valuable tool for pre-clinical research, and to expedite the clinical development of vaccines, therapeutic immunomodulatory agents, and other antiviral drug strategies for the protection of vulnerable populations against RSV disease